FDA Approved: SPIRIVA HANDIHALER — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approves a supplemental application for SPIRIVA HANDIHALER (tiotropium bromide) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE)

Snippet

SUPPL AP for SPIRIVA HANDIHALER (TIOTROPIUM BROMIDE)